Web-based Methodology Trial to Evaluate the Efficacy and Safety of Tolterodine ER in Subjects With Overactive Bladder
Status:
Terminated
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
To compare the effect of tolterodine ER 4 mg to placebo on patient reported outcomes in
subjects with overactive bladder after 1, 4, and 12 weeks of treatment using an innovative
web-based trial design
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.